Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.06 USD
Change Today -0.006 / -9.09%
Volume 368.9K
GTHP On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

guided therapeutics inc (GTHP) Snapshot

Open
$0.07
Previous Close
$0.07
Day High
$0.07
Day Low
$0.06
52 Week High
09/4/14 - $0.38
52 Week Low
08/18/15 - $0.04
Market Cap
6.8M
Average Volume 10 Days
1.2M
EPS TTM
$-0.12
Shares Outstanding
113.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GUIDED THERAPEUTICS INC (GTHP)

Related News

No related news articles were found.

guided therapeutics inc (GTHP) Related Businessweek News

No Related Businessweek News Found

guided therapeutics inc (GTHP) Details

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company primarily develops LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. It is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.

38 Employees
Last Reported Date: 07/30/15
Founded in 1992

guided therapeutics inc (GTHP) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $450.0K
Senior Vice President of Engineering and Secr...
Total Annual Compensation: $203.0K
Chief Scientific Officer
Total Annual Compensation: $277.7K
Compensation as of Fiscal Year 2014.

guided therapeutics inc (GTHP) Key Developments

Guided Therapeutics Advances LuViva PMA Application with FDA

Guided Therapeutics Inc. announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. In its “pre-submission” letter, the Company also requested a meeting with the agency to finalize the plan. At the suggestion of the FDA, the Company plans to collect additional scans on patients within the context of new cervical cancer screening guidelines recently published by the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. The letter provides a proposal for a confirmatory study to supplement data previously provided to the agency. In the meeting, the company hopes to gain agreement from the FDA on the study design.

Guided Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015

Guided Therapeutics Inc. reported unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company’s sales – devices and disposables were $103,000 against $201,000 a year ago. Operating loss was $1,601,000 against $2,027,000 a year ago. Loss before income tax was $1,706,000 against $2,152,000 a year ago. Net loss attributable to common stockholders was $3,001,000 against $2,193,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.03 against $0.03 a year ago. The decrease in revenue was primarily the result of shipments of 5 units of LuViva® Advanced Cervical Scans and 1,300 single-use disposables in the current period, compared to 11 LuViva devices and 4,200 disposables shipped in the same period of 2014. For the six months, the company’s sales – devices and disposables were $229,000 against $323,000 a year ago. Operating loss was $3,074,000 against $4,106,000 a year ago. Income before income tax was $123,000 against loss of $3,714,000 a year ago. Net loss attributable to common stockholders was $4,277,000 against $3,803,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.04 against $0.05 a year ago.

Guided Therapeutics, Inc to Report Q2, 2015 Results on Aug 12, 2015

Guided Therapeutics, Inc announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GTHP:US $0.06 USD -0.006

GTHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.70 USD 0.00
Hologic Inc $37.88 USD +0.66
Mauna Kea Technologies €3.06 EUR +0.06
MELA Sciences Inc $1.19 USD -0.01
Verisante Technology Inc C$0.09 CAD +0.005
View Industry Companies
 

Industry Analysis

GTHP

Industry Average

Valuation GTHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GUIDED THERAPEUTICS INC, please visit www.guidedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.